Pustular psoriasis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pustular psoriasis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Spesolimab Treatment for Patients with Generalized Pustular Psoriasis from Previous Trials https://clinicaltrials.eu/trial/study-on-long-term-spesolimab-treatment-for-patients-with-generalized-pustular-psoriasis-from-previous-trials/ Wed, 29 Apr 2026 14:57:04 +0000 https://clinicaltrials.eu/trial/study-on-long-term-spesolimab-treatment-for-patients-with-generalized-pustular-psoriasis-from-previous-trials/ This clinical trial is focused on studying the long-term effects of a treatment called spesolimab in people with a skin condition known as Generalized Pustular Psoriasis (GPP). GPP is a rare and severe form of psoriasis characterized by widespread pustules, which are small, pus-filled blisters on the skin. The treatment being tested, spesolimab, is a medication of biological origin, meaning it is made from living organisms or their products. It is administered either as a solution for infusion, which is delivered directly into the bloodstream through a vein, or as a solution for injection using a pre-filled syringe.

The purpose of this study is to evaluate the long-term safety and effectiveness of spesolimab in patients who have previously participated in spesolimab trials and are eligible to continue treatment. Participants in this study will receive spesolimab over an extended period, with the aim of understanding how well the treatment works and how safe it is for long-term use. The study will monitor for any side effects that may occur during the treatment period, which can last up to 252 weeks.

Throughout the study, researchers will also observe how the treatment affects the symptoms of GPP, such as the presence of pustules and overall skin condition. The study will help determine if spesolimab can maintain its effectiveness over time and improve the quality of life for those living with GPP. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Study on Spesolimab for Treating Recurrent Flares in Patients with Generalized Pustular Psoriasis https://clinicaltrials.eu/trial/study-on-spesolimab-for-treating-recurrent-flares-in-patients-with-generalized-pustular-psoriasis/ Wed, 29 Apr 2026 14:26:40 +0000 https://clinicaltrials.eu/trial/study-on-spesolimab-for-treating-recurrent-flares-in-patients-with-generalized-pustular-psoriasis/ This clinical trial is focused on studying (GPP), a rare and severe skin condition characterized by widespread pustules, which are small, pus-filled blisters. The trial aims to evaluate the effectiveness and safety of a treatment called , which is administered through an intravenous infusion, meaning it is given directly into a vein. Spesolimab is being tested to see if it can help people who experience repeated flare-ups of GPP after their initial treatment with the same medication.

The purpose of the study is to assess how well spesolimab works in managing these recurrent flare-ups. Participants in the study will receive spesolimab infusions and will be monitored to see if their skin condition improves, specifically looking for a reduction in pustules. The study will also observe any side effects and how the body responds to the medication over time.

Throughout the study, participants will have regular check-ups to track their progress and ensure their safety. The trial is designed to provide valuable information on the use of spesolimab for treating GPP, potentially offering a new option for managing this challenging condition. The study does not involve a placebo, meaning all participants will receive the active treatment.

]]>